Renaissance Technologies
BCLI

Renaissance Technologies’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Renaissance Technologies’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13,573
Closed -$41K – 3738
2023
Q3 		$41K Sell
13,573
-214
-2% -$4.87K ﹤0.01% 3433
2023
Q2 		$426K Buy
+13,787
New +$571K ﹤0.01% 2961
2023
Q1 		– Sell
-787
Closed -$19K – 3975
2022
Q4 		$19K Sell
787
-2,926
-79% -$109K ﹤0.01% 3970
2022
Q3 		$246K Buy
3,713
+2,573
+226% +$129K ﹤0.01% 3289
2022
Q2 		$47K Buy
+1,140
New +$51.3K ﹤0.01% 4003
2021
Q3 		– Sell
-3,173
Closed -$181K – 3472
2021
Q2 		$181K Buy
+3,173
New +$170K ﹤0.01% 3265
2021
Q1 		– Sell
-1,827
Closed -$124K – 3308
2020
Q4 		$124K Buy
+1,827
New +$249K ﹤0.01% 3229
2020
Q3 		– Sell
-9,416
Closed -$1.58M – 3375
2020
Q2 		$1.58M Sell
9,416
-29,027
-76% -$3.13M ﹤0.01% 2309
2020
Q1 		$2.68M Buy
38,443
+16,181
+73% +$1.26M ﹤0.01% 1902
2019
Q4 		$1.43M Buy
22,262
+2,453
+12% +$142K ﹤0.01% 2471
2019
Q3 		$1.16M Buy
19,809
+4,851
+32% +$286K ﹤0.01% 2536
2019
Q2 		$886K Buy
14,958
+1,448
+11% +$84.3K ﹤0.01% 2735
2019
Q1 		$880K Buy
13,510
+1,346
+11% +$76.6K ﹤0.01% 2724
2018
Q4 		$648K Buy
12,164
+3,237
+36% +$159K ﹤0.01% 2764
2018
Q3 		$511K Buy
8,927
+1,234
+16% +$74.6K ﹤0.01% 2840
2018
Q2 		$450K Buy
7,693
+1,753
+30% +$103K ﹤0.01% 2862
2018
Q1 		$281K Sell
5,940
-1,697
-22% -$85.4K ﹤0.01% 3100
2017
Q4 		$449K Buy
7,637
+6,100
+397% +$365K ﹤0.01% 2912
2017
Q3 		$95K Buy
+1,537
New +$99.5K ﹤0.01% 3083

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Renaissance Technologies's BCLI Position: Q4 2023 in Review

Renaissance Technologies sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2023, closing a stake of 13,573 shares — an estimated $41K sold.

Renaissance Technologies first reported a position in BCLI in Q3 2017 and held it in 19 quarters. The position peaked at $2.68M in Q1 2020. 46 funds tracked by Wall St. Rank hold BCLI as of Q4 2023.

  • Renaissance Technologies reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2023 after selling out during the quarter.
  • Renaissance Technologies sold 13,573 BRAINSTORM CELL THERAPUTC shares in Q4 2023, an estimated $41K.
  • Renaissance Technologies first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2017 and held it in 19 quarters.
  • Renaissance Technologies's BRAINSTORM CELL THERAPUTC position peaked at $2.68M in Q1 2020.
  • 46 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2023.

Based on Renaissance Technologies's 13F filing for Q4 2023, filed 13 Feb 2024.